In the current study, we examined the effects of the non-psychoactive cannabinoid, cannabidiol, on the induction of apoptosis in leukemia cells. Exposure of leukemia cells to cannabidiol led to CB2-mediated reduction in cell viability and induction in apoptosis. Furthermore, cannabidiol treatment led to a significant decrease in tumor burden and an increase in apoptotic tumors in vivo. Mechanistically, cannabidiol exposure resulted in activation of caspase-8, caspase-9, and caspase-3, cleavage of PARP and a decrease in full-length Bid, suggesting possible cross-talk between the intrinsic and extrinsic apoptotic pathways. The role of the mitochondria was further suggested as exposure to cannabidiol led to loss of mitochondrial membrane potential and release of cytochrome C. Interestingly, cannabidiol exposure led to an increase in reactive oxygen species (ROS) production as well as an increase in the expression of the NAD(P)H oxidases, NOX4 and p22
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Although a number of reports demonstrate the ability of CBD to induce apoptosis in tumor cells, little work has been done demonstrating CBD mechanism of action. Massi et al. found that apoptosis in human glioma cell lines following exposure to CBD was mediated through CB2 receptor and the generation of reactive oxygen species (ROS).The generation of ROS can play an important role in the induction of apoptosis in T cells undergoing either activation induced cell death (AICD) or activated T cell autonomous cell death (ACAD) (Hildeman et al., 2003) . Furthermore, the regulation of ROS generation can be significantly impacted by NAD(P)H oxidases (Lee et al., 2000; Suzuki et al., 1998) . Numerous studies have been carried out examining the ability of compounds to induce apoptosis in tumor cells by increasing ROS production (Chang et al., 2005; Hu and Brindle, 2005; Kang et al., 2004; Kim et al., 2004; Lebedeva et al., 2005) . However, little is known about the ability of cannabinoids or signaling through cannabinoid receptors to regulate the expression or activity of NAD(P)H oxidases and/or to control of ROS generation in leukemia. However in a recent study, the NAD(P)H oxidase NOX 5, which plays a significant role in mediating Ca 2+ -dependent ROS generation, was shown to be expressed in lymph nodes and the spleen, suggesting a possible role of NAD(P)H oxidases in the regulation of ROS production in cells of the immune system (Banfi et al., 2001 ).
The observation that CBD can mediate apoptosis through cannabinoid receptor 2 (CB2) combined with results from our previous study, where we demonstrated that when compared to a human glioma cell line, a number of human leukemias and lymphomas expressed significantly higher levels of CB2, suggests the possibility that human leukemias and lymphomas may be highly sensitive to the CB2-mediated effects of cannabidiol (Massi et al., 2004; McKallip et al., MOL 23937 concentrations of cannabidiol. Finally, the cells were harvested, washed twice in PBS and the viable cell count was determined by trypan blue dye exclusion.
Detection of cannabidiol-induced apoptosis in vitro.
Tumor cells (0.5 x 10 6 cells/well) were cultured in 24-well plates in the presence or absence of various concentrations of cannabidiol and/or cannabinoid receptor antagonists for 24 h. Next, the cells were harvested, washed twice in PBS and analyzed for the induction of apoptosis using the TUNEL or Wright-Giemsa method.
To detect apoptosis using the TUNEL method the cells were washed twice with PBS and fixed with 4% p-formaldehyde for 30 minutes at room temperature. The cells were next washed with PBS, permeabilized on ice for 2 minutes and incubated with FITC-dUTP and TdT (Boehringer Mannheim, Indianapolis, IN) for 1 hour at 37 0 C and 5% CO 2 . Five thousand cells were analyzed per sample. To detect apoptosis using the Wright-Giemsa method centrifuged preparations were stained with Wright-Giemsa stain and observed by light microscopy for signs of apoptosis including nuclear condensation, cell shrinkage, and formation of apoptotic bodies (Jia et al., 2003) .
Measurement of tumor cell viability and induction of apoptosis in vivo.
Groups of 5 C57BL/6 mice were injected with 1 x 10 6 EL-4 tumor cells i.p suspended in 0.2 ml PBS. The control mice received PBS alone. Ten days later, the mice were injected with various concentrations of cannabidiol (0, 12.5 or 25 mg/kg) i.p. The mice were sacrificed 24 hours later and the EL-4 tumor cells were harvested from the peritoneal cavity by injecting 5.0 ml PBS, followed by aspiration of the peritoneal fluid from the cavity. The contaminating red blood cells were removed using red blood lysing solution (Sigma, St. Louis, MO) and the tumor cells were This article has not been copyedited and formatted. The final version may differ from this version. The labeled cells were then exposed to various concentrations of CBD for 24h and the levels of ROS were determined by flow cytometric analysis and changes in ROS levels were depicted as the percent increase in fluorescence. BSA for 1h at room temperature. The membrane was rinsed and then washed 3 times for 10 minutes with TBS containing 0.1% Tween 20. The membrane was then probed with the specific primary antibody in 5% blocking solution overnight at 4 0 C. The membrane was then rinsed and washed 3 times with TBS containing 0.1% Tween 20 and probed with the appropriate HRP-conjugated secondary antibody for 1 hr at room temperature. The proteins were then visualized following incubation with ECL solution and exposure to X-ray film.
Analysis of protein expression by
Assessment of cytosolic cytochrome c levels. Jurkat cells were harvested and centrifuged at 600g for 10 minutes. The cells were then lysed using 100 µ l lysing buffer (75 mM NaCl, 8mM Na 2 HPO 4 , 1mM
NaH 2 PO 4, 1mM EDTA, and 350 µ g/ml digitonin). Next, the lysates were centrifuged at 12,000g for 5 minutes. The proteins from resulting fraction (S-100) were quantified, separated by SDS-PAGE electrophoresis and probed using mAb specific for cytochrome C. This article has not been copyedited and formatted. The final version may differ from this version. 
Results
Exposure of EL-4 to cannabidiol leads to a reduction in viability and induction of apoptosis in vitro. We examined whether cannabidiol-exposure had an effect on the viability of EL-4, tumor cells in vitro. To this end, the tumor cells were cultured in serum-free medium and exposed to various concentrations of cannabidiol (0, 1.25, 2.5, 5 and 10 µM) for 24 hours and the viability was determined by trypan blue dye exclusion ( Figure 1A) . The results showed that exposure to cannabidiol at concentrations of 2. Figure 2B ). These data suggested that cannabidiol was effective at killing the EL-4 tumor cells in vivo by inducing apoptosis.
Cannabidiol induces apoptosis in human leukemia cells in vitro. Next, we examined whether exposure of human leukemia cells to cannabidiol would lead to induction of apoptosis. To this end, Jurkat and MOLT-4 cells were exposed to various concentrations of cannabidiol (2.5, and 5 µM) or the vehicle for 24 h, and the effect on cell viability was determined by trypan blue dye exclusion and the induction of apoptosis was determined using the TUNEL method. The results showed that exposure of the Jurkat or MOLT-4 cells to > 2.5 µM cannabidol led to significant decrease in the tumor cell viability ( Figure 3A ) and an increase in the levels of apoptosis ( Figure   3B ). Fig 3B shows a representative experiment using TUNEL assay. Next, experiments were set up to determine the earliest time point in which CBD-induced apoptosis could be detected. To this end, Jurkat cells were cultured with CBD (5.0 µ M) for 8, 16, and 24h ( Figure 3C ). The effect of CBD on the induction of apoptosis at the various time points was determined using the TUNEL assay and revealed that significant CBD-induced apoptosis could be detected following or VR1 antagonist was unable to prevent cannabidiol-induced apoptosis (data not shown).
Together, these results suggested that cannabidiol-induced reduction in viable cell number and the induction of apoptosis of Jurkat cells was mediated through CB2.
Cannabidiol induces activation of the caspase cascade through CB2. The activation of the caspase cascade is commonly associated with the induction of apoptosis. Therefore, to further investigate the mechanism of cannabidiol-induced apoptosis, we examined the activation pattern of caspases following CBD exposure. To this end, Jurkat cells were exposed to various concentrations of cannabidiol (2.5 and 5 µM) or the vehicle for 24 hours. Next, the cells were harvested and the presence of the various caspases was determined by Western blot analysis ( Figure 5A ). The results demonstrate that exposure to CBD at concentrations of 2.5 µ M or greater led to activation of the caspase cascade. More specifically, we observed cleavage of caspase-8, and reduction in procaspase-2, -9, and -10, which are thought to be involved in initiating the caspase cascade. In addition, the cleavage of the effector type caspase-3 and PARP were observed following exposure to CBD. Next, the involvement of CB2 was examined by culturing Jurkat cells with the CB2 antagonist, SR144528, in the presence or absence of CBD.
The results showed that the CB2 antagonist was able to significantly prevent CBD-mediated induction of the caspase cascade. Interestingly, CBD-induced cleavage of Bid was observed in
Jurkat cells suggesting possible cross-talk between the intrinsic and extrinsic apoptotic pathways.
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Together, these results suggest a direct role of the mitochondria in CBD-induced apoptosis.
CBD induces increased generation of ROS. CBD exposure has been associated with increase levels of ROS in glioma cells (Massi et al., 2004) . Furthermore, ROS have been associated with activation of the intrinsic apoptotic pathway (Singh et al., 2005; Zorov et al., 2000) . Therefore, in the current study we examined the effect of CBD-exposure on Jurkat production of ROS. The results showed that exposure of Jurkat and MOLT-4 cells to 2.5 µ M or greater CBD for 24h led to a significant increase in the levels of ROS production ( Figure 6A ). The involvement of the CBD-induced increase in ROS generation in Jurkat apoptosis was further confirmed using the ROS scavengers, α-tocopherol and NAC. More specifically, Jurakat cells were exposed to CBD + α-tocopherol or CBD + NAC and then analyzed for viable cell number ( Figure 6B ), induction of apoptosis ( Figure 6C ) and ROS production ( Figure 6D ). The results demonstrated that treatment with ROS scavengers led to a significant reduction in CBD-induced Jurkat cell killing and apoptosis. Furthermore, the degree to which the ROS scavengers prevented the effects of CBD on tumor cell killing directly correlated with the ability of the scavengers to reduce the level of CBD-induced ROS.
This article has not been copyedited and formatted. The final version may differ from this version. Sim et al., 2005; Suzuki et al., 1998) . Therefore, we examined whether exposure of Jurkat cells to CBD had an effect on the expression of NAD(P)H oxidases. In initial experiments, the effect of CBD on NAD(P)H oxidases was screened using RT-PCR. These studies revealed that CBD exposure led to a significant increase in the levels of Nox4 and p22 phox , while the expression of other NAD(P)H oxidases, including Nox1, Nox2, Nox3, Nox5, p47 phox , and p67 phox was unaffected (data not shown). The effect of CBD on Nox4 and p22 phox were confirmed by Western blot analysis (Fig. 7A) . Furthermore, the role of CB2 in CBDinduced alteration in Nox4 and p22 phox expression was confirmed. More specifically, treatment with the CB2-selective antagonist inhibited the CBD-induced effects on Nox4 and p22 phox protein expression (Fig. 7A ). The role of NAD(P)H oxidases in CBD-induced killing of Jurkat cells was further confirmed using the NAD(P)H oxidase inhibitors, diphenylene iodinium (DPI) and apocynin, demonstrating that treatment with NAD(P)H inhibitors led to a significant reduction in both CBD-induced cell toxicity ( on the levels of the phosphorylated forms of these signaling molecules. To this end, Jurkat cells were exposed for 4 or 16h to vehicle or 5 µ M CBD. Next, the cells were stained with mAbs specific for ERK, p-ERK, JNK, p-JNK, p38 and p-p38 MAPK and analyzed by flow cytometric analysis ( Figure 8A ). The results demonstrated that exposure to CBD for 16h led to a significant reduction in the levels of p-p38 MAPK, while p-JNK and p-ERK were unaffected. The effect of CBD on the levels of p-p38 were confirmed by Western blot analysis, where it was shown that following 16h of exposure, CBD led to a significant reduction in the levels of p-p38 ( Figure 8B ).
No significant effects on p-p38 were seen following 4 or 8h exposure to CBD. The involvement of CB2 in the downregulation of these signaling molecules was examined by pre-exposing the Jurkat cells to the CB2-selective antagonist SR144528 and the results showed that the CBDmediated effects on p-p38 were dependent on CB2 signaling ( Figure 8C ). Furthermore, the role of ROS generation in the CBD-mediated reduction of p-p38 was examined by treating Jurkat cells with α-tocopherol prior to CBD exposure. The results from this experiment demonstrated that treatment with the ROS scavenger was able to prevent the reduction of p-p38 following CBD exposure, suggesting that the effects on ROS generations were upstream of the effects on p38 ( Figure 8C ).
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In the current study, we demonstrated that cannabidiol can induce apoptosis in murine as well as human leukemia cells. Cannabidiol-induced apoptosis was mediated through CB2, as treatment with a CB2-selective antagonist, but not CB1-selective or VR1-selective antagonist, was able to significantly reduce the levels of apoptosis following cannabidiol exposure.
Furthermore, cannabidiol was effective in vivo as treatment with cannabidiol led to a significant reduction in tumor burden and an increase in the level of apoptotic tumors in EL-4 bearing mice.
Together these data suggest that cannabidiol may be a novel treatment of leukemia.
Previously, we demonstrated that treatment with THC led to significant levels of apoptosis in a number of leukemias (McKallip et al., 2002) . Cannabidiol lacks any significant psychotropic activity. Therefore, its use in the treatment of human diseases may be preferable when compared to THC or other psychoactive cannabinoids. Importantly, we show that CBD and other cannabinoids such as THC have similar anticancer activity. For example, we demonstrated significant levels of apoptosis in both human and mouse leukemia cell lines following exposure to > 2.5 µ M CBD. These levels were similar to reported levels of THC necessary to induce apoptosis in these cell lines (McKallip et al., 2002) . Furthermore, evidence suggests that the doses of CBD used in vitro in the current study were pharmacologically relevant. This is supported by an earlier study in which rats injected with 50 mg/kg of the cannabinoid, THC were shown to exhibit 10 µM of THC in the serum within 10 hours of administration (Chan et al., 1996) .
In a recent study, exposure of glioma cells to 25 showed that the CBD-mediated suppression of glioma cell migration was through a cannabinoid receptor-independent mechanism (Vaccani et al., 2005) . Additionally, studies have implicated VR1 in CBD-mediated effects (Bisogno et al., 2001 ). Furthermore, due to the lipophilic properties of CBD, nonspecific killing through intercalation into the cell membrane may also influence CBD's activity. However, in the current study, we demonstrated that treatment with the CB2-selective antagonist SR144528 led to significant inhibition of CBD-mediated apoptosis in Jurkat cells. This effect was specific for CB2, as treatment with CB1-or VR1-antagonists was ineffective at preventing CBD-mediated apoptosis (data not shown).
Currently, compounds that can influence the generation of ROS are being examined for their potential use in the treatment of a number of diseases including cancer (Chang et al., 2005; Hu and Brindle, 2005; Kang et al., 2004; Kim et al., 2004; Lebedeva et al., 2005) . However, little has been reported regarding the ability of cannabinoids to regulate the generation of ROS.
In a study examining the effect of CBD on glioma cells, CBD-induced apoptosis was related to increased ROS generation (Massi et al., 2004 ). In the current study, we demonstrated a similar In contrast, it was reported that NOX4 played a significant role in mediating apoptosis in human aortic smooth muscles cells following exposure to 7-ketocholesterol (Pedruzzi et al., 2004) . To date, expression of these enzymes and their contribution to the induction of apoptosis in leukemia cells has not been reported. In the current study, we demonstrated that CBD exposure led to increased expression of the NAD(P)H oxidases, Nox4 and p22 phox , suggesting the possibility that regulation of these enzymes and the subsequent generation of ROS may play a significant role in the induction of apoptosis in leukemia cells. Therefore, targeting Nox4 and p22 phox using CBD may be a novel approach for treating malignancies of the immune system. This article has not been copyedited and formatted. The final version may differ from this version. The mechanism by which CBD exposure leads to increased expression of NOX4 and p22 phox is not clear. However, initial observations in this study showing that pretreatment with CB2-selective antagonist, but not CB1-or VR1-selective antagonists significantly inhibited the CBD-mediated increase in NOX4 and p22 phox expression, suggests that CBD regulation of these enzymes is mediated through CB2 activation. Interestingly, the mechanism of action seems to be distinct from that of THC, which can lead to increased ceramide production and has been associated with G-protein coupled receptor signaling (Galve-Roperh et al., 2000; Rueda et al., 2000) . In the current study, we were unable to block CBD-induced apoptosis using various inhibitors of ceramide generation or pertussis toxin, which blocks G-protein coupled receptor signaling (data not shown). Taken together, these data suggest that although both THC and CBD exposure can lead to the induction of apoptosis in leukemia cells, their mechanisms of action may be distinct from one another. Therefore, treatments using the combination of THC and CBD may significantly enhance the efficacy of tumor killing. To date, this approach has not been reported for the treatment of leukemia or lymphoma. However, initial studies demonstrated that the combination of CBD and THC was better tolerated than THC alone (reviewed in Russo, 2005) , possibly allowing for the use of increased levels of THC without the unwanted psychoactive side effects. In fact, it was shown that CBD could antagonize some of the undesirable effects of THC, such as its psychoactive properties, by blocking conversion of THC to the more psychoactive 11-hydroxy-THC (Bornheim and Grillo, 1998) In addition, results from this study demonstrated that CBD exposure led to the reduction of p-p38 levels, while p-ERK and p-JNK levels were unaffected. Support for the role of p38 in CBD-induced apoptosis come from reports that demonstrate that CBD exposure led to reduced levels of p-p38 in PC12 neuronal cells (Esposito et al., 2006) . Furthermore, in a separate study it was shown that reduction in p-p38 levels in Jurkat cells led to the induction of apoptosis (Nemoto et al., 1998) . Taken together, these results suggest that CBD-induced apoptosis is regulated, at least in part, through alterations in p38 signaling.
In summary, the current study demonstrates that CBD-induced apoptosis may constitute a novel approach to treat malignancies of the immune system. CBD has been reported to be nonpsychoactive, making it more attractive than its psychoactive counterpart, THC, as a therapeutic agent. Here we found that the CBD-induced apoptosis was dependent on CB2 receptor signaling. 
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